The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine nasal spray ... to give numbers for Singapore, but Spravato is available at about 2,800 ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray ... the ketamine nasal spray Spravato is now a mainstream prescription for ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision ...

SPRAVATO® (Esketamine): SPRAVATO® is an innovative treatment for treatment-resistant depression or depression with suicidal thoughts or actions. Administered under medical supervision, this ...

Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting ...